Armistice Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Armistice Capital’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.6M	Hold	2,000,000	–	–	0.33%	50
2026 Q1	$18.6M	Buy	2,000,000 +64,000	+3%	+$557K	0.33%	61
2025 Q4	$14.5M	Buy	1,936,000 +840,000	+77%	+$8.52M	0.17%	89
2025 Q3	$9.52M	Buy	1,096,000 +796,000	+265%	+$4.76M	0.14%	88
2025 Q2	$1.11M	Hold	300,000	–	–	0.02%	146
2025 Q1	$969K	Hold	300,000	–	–	0.01%	167
2024 Q4	$1.67M	Sell	300,000 -36,000	-11%	-$283K	0.02%	159
2024 Q3	$3.63M	Buy	+336,000	New	+$5.58M	0.06%	137

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Armistice Capital's FDMT Position: Q2 2026 in Review

Armistice Capital held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 2,000,000 shares worth $26.6M. The position accounts for 0.33% of the portfolio, ranked #50.

Armistice Capital first reported a position in FDMT in Q3 2024 and has held it in 8 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Armistice Capital held 2,000,000 shares of 4D Molecular Therapeutics worth $26.6M as of Q2 2026.
Armistice Capital left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
4D Molecular Therapeutics made up 0.33% of Armistice Capital's portfolio in Q2 2026, its #50 holding.
Armistice Capital first reported a position in 4D Molecular Therapeutics in Q3 2024 and has held it in 8 quarters since.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.